In chemical process development, route scouting during active pharmaceutical ingredient (API) development is a strategy that can influence how successfully an API moves from the lab to clinical trials and commercial production.
Image Credit: Concept Life Sciences
Pharmaceutical and biotech companies are under increasing pressure to develop safe, effective, and cost-efficient treatments faster than ever. Rigorous route scouting has emerged as a vital risk-reduction phase in API development, assisting teams in identifying scalable, cost-effective, and robust synthetic pathways early on.
This article discusses when route scouting is most important and outlines a methodical approach for its execution that ensures the chosen synthetic route is phase-appropriate, fit for purpose, and suitable for large-scale pharmaceutical production.
What is route scouting in API development?
Route scouting in API development is the process of locating, analysing and choosing the most efficient and scalable synthetic pathway for producing an API. It is critical for lowering risk, controlling expenses, and allowing successful process scale-up.
When is route scouting important in API development?
Route scouting is a continuous practice that occurs throughout the API development lifecycle. Its importance grows as the API progresses from concept to clinic
Early discovery phase
When chemists first find compounds with therapeutic potential, route scouting can help them quickly create a viable synthetic method. The emphasis at this step is on accessibility, not optimization, ensuring that the drug can be generated in sufficient quantity and purity for initial biological testing.
Even at this early stage, comparing different synthetic methods can be beneficial. This exercise can highlight paths that are better suited to future scale-up or improve impurity control.
Pre-clinical and clinical phase transitions
As an API progresses through pre-clinical and clinical development stages, material demand rises and purity, safety, and repeatability requirements grow increasingly important.
Route scouting becomes critical in ensuring the synthetic process can be scaled efficiently while consistently meeting quality and process requirements. At small scale, impurities can often be removed relatively easily through purification steps; however, at larger manufacturing scales, relying on extensive purification becomes inefficient, costly, and wasteful. Early route evaluation, therefore, focuses not only on minimizing impurity formation but also on understanding the nature of those impurities and assessing any potential toxicological liabilities. Where problematic impurities are identified, process strategies can be implemented to either eliminate their formation or ensure they are effectively purged at later stages of the synthetic route. This proactive approach helps create more robust, scalable, and commercially viable manufacturing processes.
The early identification and elimination of these risks prevents delays and costly rebuilding. At this step, route scouting must consider patient safety.
Late-stage development and commercial manufacturing
As an API progresses into late-stage clinical trials and towards commercialization, the focus shifts from route scouting to optimization of the selected synthetic route. At this stage, development efforts concentrate on refining reaction conditions and improving process robustness to enhance scalability, cost-efficiency, and sustainability. This may involve optimizing yields, reducing impurity formation, improving process efficiency, and ensuring the route can reliably support larger-scale manufacturing requirements.
At this stage, the goal is to establish a robust synthetic process that can be reliably scaled while consistently maintaining product quality, regulatory compliance, and commercial viability.
Route selection: A structured approach in chemical process development
At Concept Life Sciences, we believe that a successful API development campaign necessitates a methodical, multidisciplinary approach to route scouting that combines chemistry, process engineering, and strategy.
1. Define objectives and requirements
The first stage is to clearly define the project goals and constraints. These typically include required API quantity and purity, development timelines, regulatory requirements, and target cost considerations.
For early-stage development, speed and material availability may be the priority. Scalability, robustness, and product cost are essential factors in commercial production. Aligning route scouting with these objectives in mind ensures that resources are directed toward feasible alternatives.
2. Generate and evaluate synthetic routes
Several viable synthetic methods should be identified using scientific publications and databases, patent databases, and internal knowledge.
Each route should be assessed based on key criteria:
- Chemical feasibility: the robustness of the chemical transformations
- Material availability: the cost and supply of starting materials and reagents
- Environmental impact and safety considerations: including hazardous reagents and waste management
- Scalability: suitability for increased throughput
- Controlling impurities: particularly those that are genotoxic
Using a scoring system or decision matrix allows for objective assessment and prioritization of the most promising options.
3. Conduct experimental validation
Following this evaluation, shortlisted routes are assessed through small-scale experimental studies to confirm their practicality and performance. Key considerations include yield, selectivity, reaction efficiency, and the ease of product isolation and purification, while ensuring the process can deliver reproducible results under varying conditions.
4. Optimize the selected route
Once a route has been selected, the optimization process begins. This includes fine-tuning reaction conditions, selecting appropriate reagents and solvents, and refining purification strategies. Process development principles are applied to improve robustness, safety, efficiency, and scalability. In some cases, technologies such as continuous processing may be explored to increase productivity and reduce manufacturing timelines.
Scale-up activities are typically performed in stages, beginning with pilot-scale studies to identify potential process risks and liabilities before progressing to commercial production. Close collaboration with manufacturing teams helps ensure the process aligns with the facility's capabilities and operational requirements. This stage is critical for identifying and mitigating risks early, while maintaining consistent process performance throughout clinical and commercial production.
5. Assess regulatory compliance
Regulatory issues must be integrated into the route scouting and process optimization workflows.
This includes adhering to GMP standards and coordinating with regulatory organizations such as the FDA and EMA. Comprehensive documentation is required to support regulatory filings and inspections, including experimental results, process parameters, and impurity profiles.
Early contact with authorities can assist in identifying potential concerns and streamlining the approval processes.
Key benefits of route scouting in API development
- Enables smooth transition to commercial manufacturing
- Boosts cost efficiency and process resilience
- Improves impurity control and product quality
- Minimizes scale-up and manufacturing risk
- Ensures regulatory compliance
Conclusion
Route scouting is a vital component of chemical process development and is essential for successful API development. Organizations can use it strategically throughout the development lifecycle to find synthetic paths that are scalable, cost-effective, and fit for purpose.
An organized, multidisciplinary approach to route scouting reduces risk, shortens development times, and facilitates the delivery of high-quality medications to patients. As the pharmaceutical industry evolves, route scouting will remain an important driver of innovation, efficiency, and commercial success.
Acknowledgments
Produced using materials originally authored by David Fengas from Concept Life Sciences.
About Concept Life Sciences
Concept Life Sciences is a leading contract research organisation (CRO) serving the global life sciences industry. For over 25 years, the company, and its heritage companies, have provided consultative and collaborative drug discovery and development services. Our approach, supported by passionate scientists and world-leading capabilities, enables clients to overcome complex scientific challenges across a broad range of therapeutic areas, improving program success rates. The company has successfully helped 29 candidates advance to the clinic.
The company offers sophisticated translational biology services coupled with exceptional end-to-end chemistry capabilities across all modalities, including small molecules, biologics, peptides and cell & gene therapies, with the ability to seamlessly integrate capabilities and provide bespoke solutions to address client needs.
Collectively, the company’s high-quality services and commitment to customer service across the drug development pathway enhance efficiency in drug discovery, helping clients advance their drugs to clinic in as little as 32 months, well ahead of the industry average of 60 months.
Driven by a passion for science, Concept Life Sciences has around 230 employees, with around 70 % holding PhDs. The company operates from state-of-the-art UK facilities, headquartered near Manchester, with additional operations in Edinburgh, Dundee, and Sandwich. The headquarters is one of the UK’s largest medicinal chemistry CRO sites with key discovery services all under one roof.
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.net, which is to educate and inform site visitors interested in medical research, science, medical devices, and treatments.